Vertex Pharmaceuticals (VRTX) Rating Reiterated by JPMorgan Chase & Co

Lloyd Doyle
January 13, 2018

The firm owned 4,782,993 shares of the company's stock after buying an additional 163,895 shares during the period. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The stock was sold at an average price of $155.19, for a total value of $266,616.42. Another trade for 2,155 shares valued at $332,236 was sold by SMITH IAN F. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since January 11, 2017 and is uptrending. It has underperformed by 20.11% the S&P500.

Investors sentiment decreased to 0.88 in 2017 Q3. Its down 6.30, from 7.64 in 2017Q2. It is negative, as 5 investors sold SGA shares while 10 reduced holdings. 79 funds opened positions while 217 raised stakes. The hedge fund run by Joseph Edelman held 138,626 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $21.08 million, down from 277,352 at the end of the previous reported quarter. However, technicians believes that a higher ratio would indicate the likelihood of a constant augmentation of the company's share price. California State Teachers Retirement has invested 0% in Saga Communications, Inc. Mirae Asset Glob Limited accumulated 30,808 shares. Ajo Limited Partnership reported 514,719 shares. Schwab Charles Invest Management owns 0% invested in Saga Communications, Inc. Engineers Gate Manager L P invested in 27,866 shares or 0.1% of the stock. Legal & General Grp Plc accumulated 0% or 1,285 shares. Financial Bank Of Nova Scotia reported 43,760 shares. Advisor Prtnrs Limited Liability Company holds 0.04% or 5,372 shares in its portfolio. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. The insider Knobel Jeff A sold $209,326. 2,330 shares were sold by Parini Michael, worth $362,828 on Thursday, August 3. On Wednesday, September 20 the insider Pauley Lisa Ann sold $697,110. During the same quarter a year ago, the business earned $0.17 earnings per share. With these types of results to display analysts, are more optimistic than before, leading 4 of analysts who cover The Gap, Inc. Therefore 86% are positive.

COPYRIGHT VIOLATION WARNING: "Vertex Pharmaceuticals (VRTX) Rating Reiterated by JPMorgan Chase & Co." was reported by BBNS and is the sole property of of BBNS. Oppenheimer raised their price target on Vertex Pharmaceuticals from $175.00 to $190.00 and gave the company an "outperform" rating in a report on Thursday, January 4th. As it upholds an amended rate with more EPSGR it is prone to be a good target. Their average price target spell out an upbeat performance - a 17% and would give VRTX a market capitalization of almost $45.51B. The stock has "Buy" rating by Stifel Nicolaus on Tuesday, December 1. Barclays Capital downgraded the shares of VRTX in report on Tuesday, November 29 to "Equal-Weight" rating. The firm has "Overweight" rating by JP Morgan given on Monday, August 15. The firm earned "Market Perform" rating on Thursday, April 7 by BMO Capital Markets. RBC Capital Markets maintained Parsley Energy, Inc. The rating was maintained by Maxim Group with "Buy" on Wednesday, July 19. The stock of Ball Corporation (NYSE:BLL) has "Hold" rating given on Friday, July 7 by BMO Capital Markets.

Ratings analysis reveals 40% of Vertex Pharma's analysts are positive. Zacks Investment Research upgraded Vertex Pharmaceuticals from a hold rating to a strong-buy rating and set a $176.00 price target for the company in a research note on Monday. Looking at the other side of the coin, VRTX traded as low as $77.09 in the past 52 weeks, and since then the shares have risen 102.37% or $78.92. They issued a "buy" rating and a $200.00 price target on the stock. VRTX was included in 5 notes of analysts from September 13, 2016. The company was upgraded on Wednesday, July 19 by Raymond James.

Vertex Pharmaceuticals Incorporated (VRTX) ended its previous trading session at $156.01 with the Loss of -0.56%. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is 12.4% above its 200-day moving average, providing a measure of resistance for long positions. They expect $0.28 EPS, up 115.38% or $0.15 from last year's $0.13 per share. VRTX's profit will be $70.81M for 140.52 P/E if the $0.28 EPS becomes a reality. Analysts forecast that Vertex Pharmaceuticals Incorporated will post $0.84 earnings per share for the current year. The stock increased 0.65% or $1.02 during the last trading session, reaching $158.4. As for the shares, it has gone below the 20 days moving average and is now hovering within a distance of -5.1%.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Wednesday, October 25th. It has outperformed by 28.99% the S&P500.

Since January 1, 0001, it had 0 buys, and 23 insider sales for $64.38 million activity. BTIG Research initiated coverage on shares of Vertex Pharmaceuticals in a report on Friday, September 29th. Weiss Multi owns 394,564 shares for 0.08% of their portfolio. Paradigm Asset Management Co. The New York-based Orbimed Advisors Llc has invested 3.01% in the stock. Ig Investment reported 10,500 shares stake.

Other reports by Iphone Fresh

Discuss This Article